Showing 1071-1080 of 3684 results for "".
Viewpoints: When is it Enough?
https://practicaldermatology.com/topics/general-topics/viewpoints-when-is-it-enough/21104/As MOC concerns mount, one specialist is calling for a poll of dermatologists.Of Pandemics and Postponements
https://practicaldermatology.com/topics/practice-management/of-pandemics-and-postponements/23342/Should You Restrict a Procedure?
https://practicaldermatology.com/series/editors-message/should-you-restrict-a-procedure/23931/Reflections on 25 Years of Private Practice
https://practicaldermatology.com/topics/practice-management/reflections-on-25-years-of-private-practice/20670/New In My Practice: OTC
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-otc-2/23325/News
https://practicaldermatology.com/topics/general-topics/news/21339/Comorbidities in Immune-mediated Skin Disorders: What’s Coming
https://practicaldermatology.com/issues/january-february-2025/comorbidities-in-immune-mediated-skin-disorders-whats-coming/32968/Comorbidities in immune-mediated skin disorders (IMSDs) occur frequently and have a significant impact on disease severity, treatment, prognosis, and quality of life.Endo’s Qwo for Treatment of Cellulite
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/endos-qwo-for-treatment-of-cellulite/23466/Launching soon, the first injectable to target cellulite performed well in clinical trials.2024 In Review: This Year's Trends in Dermatology
https://practicaldermatology.com/topics/feature/2024-review-years-trends-dermatology/29886/As the year comes to a close, Practical Dermatology asked Editorial Board members about trends from 2024—what was hot, what was not, new approvals that lived up to the hype, important new research, and other observations from the past year.Pulse’s CellFX for Dermatologic Applications
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pulses-cellfx-for-dermatologic-applications/23464/A novel technology targets cells to treat warts, sebaceuous hyperplasia, and more.